Ultimately, the coordination and standardized follow up protocols needed to ensure patients are engaging with the complex LS surveillance recommendations might be best accomplished within a high-risk cancer department involving multiple specialists, as has been established for patients with Hereditary Breast and Ovarian Cancer syndrome due to a pathogenic variant in BRCA1 or BRCA2 [3, 28, 29]. This evidence concerns the gene BRCA1 and Hereditary breast and ovarian cancer syndrome.